Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

terminated120%
recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.

NCT07830654
terminatedphase_1

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

NCT01515384
completedphase_2

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

NCT01550484
completedphase_1

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

NCT01710371
completedphase_1

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

NCT01503944

Clinical Trials (5)

Showing 5 of 5 trials
NCT07830654Phase 2

This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.

Recruiting
NCT01515384Phase 1

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

Terminated
NCT01550484Phase 2

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

Completed
NCT01710371Phase 1

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

Completed
NCT01503944Phase 1

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5